Equities

Synairgen PLC

Synairgen PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)6.40
  • Today's Change-0.62 / -8.83%
  • Shares traded863.43k
  • 1 Year change-44.54%
  • Beta-6.5179
Data delayed at least 20 minutes, as of Apr 24 2024 16:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company; Synairgen Inc. and Synairgen Research (Ireland) Limited. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-9.99m
  • Incorporated2004
  • Employees30.00
  • Location
    Synairgen PLCSouthampton General Hosp, Tremona RoadSOUTHAMPTON SO16 6YDUnited KingdomGBR
  • Phone+44 238 051 2800
  • Fax+44 238 051 2800
  • Websitehttps://www.synairgen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ImmuPharma PLC69.96k-2.99m9.08m13.00--4.18--129.76-0.0092-0.00920.00020.00520.0227--0.17065,381.54-97.05-89.69-159.35-106.57-----4,275.31-7,958.69---2.400.00---100.00--53.42--32.98--
Bivictrix Therapeutics PLC0.00-2.33m9.49m10.00--2.68-----0.0352-0.03520.000.04280.00----0.00-50.56---57.49--------------0.1267-------6.71------
Cambridge Nutritional Sciences PLC9.05m-3.21m9.52m91.00--1.02--1.05-0.0136-0.01050.03850.03910.58573.972.0599,406.59-20.81-10.49-23.88-11.9052.9059.24-35.53-27.404.22-128.470.0225---11.63-1.96-125.12---45.83--
Proteome Sciences plc5.03m-2.44m9.59m35.00------1.91-0.0083-0.00830.017-0.01040.42093.893.04143,657.10-20.45-1.22----32.7654.53-48.59-2.200.2667-2.031.29---35.3710.52-284.38--126.22--
Kanabo Group PLC813.00k-4.66m10.75m20.00--0.7069--13.22-0.0108-0.01080.00190.0240.0478.5627.1040,650.00-26.95-75.82-28.68-82.5723.12---572.94-1,786.107.96-13.030.041--726.03---50.96------
Shield Therapeutics PLC7.21m-46.89m11.14m28.00--0.3749--1.55-0.1549-0.15490.01510.0380.16911.800.9805---109.95-42.77-129.39-48.1244.7679.44-650.12-274.352.64-124.940.1756--261.5553.86-151.04---7.68--
Chill Brands Group PLC146.62k-3.64m11.54m2.00------78.73-0.0142-0.01420.0006-0.00240.03190.09920.363973,310.00-79.21-72.55-141.46-105.3553.05---2,485.30-1,625.460.6499-8.481.17---86.73-50.8923.50---35.95--
Abingdon Health PLC5.34m-2.24m12.78m82.00--7.05--2.39-0.0184-0.01840.04390.01490.89787.674.7465,170.73-37.55-51.31-58.04-79.8557.3533.16-41.82-139.641.59--0.3572--42.68--83.77------
Incanthera PLC0.00-1.48m12.87m8.00---------0.0192-0.01920.00-0.00860.00----0.00-373.20-101.74---132.88---------------------36.11------
Provexis plc598.08k-496.59k13.58m2.00--13.54--22.70-0.0002-0.00020.00030.00040.67173.042.95299,040.00-55.78-48.82-41.86-33.6846.7286.14-83.03-97.641.96--0.00---8.5110.58-71.79------
Synairgen plc0.00-9.99m14.14m30.00--0.8855-----0.0496-0.04960.000.07930.00----0.00-41.40-54.75-48.86-60.72-------83,247.62----0.00------63.74--0.00--
Genincode PLC1.72m-6.73m14.38m28.00--1.63--8.38-0.0703-0.07030.01790.04970.16816.362.8861,285.71-65.92---72.37--47.55---392.31--5.85--0.0632--23.92---34.21------
OptiBiotix Health PLC689.10k-13.17m17.38m3.00--1.73--25.23-0.1489-0.14890.00780.10290.04262.281.25229,700.00-81.3517.83-83.4318.6649.3154.87-1,911.88190.543.24-0.0890.00---79.3519.05-58.686.2830.03--
Oncimmune Holdings PLC1.15m-6.15m18.39m56.00--27.99--15.96-0.08590.05070.01590.00890.12391.080.5941---66.15---131.46--68.75---533.94--3.75-1.960.8897--------------
Skinbiotherapeutics PLC161.65k-2.88m18.54m11.00--4.82--114.66-0.0165-0.01650.00090.01920.05220.88710.418114,695.45-93.07-52.07-115.26-57.3362.90---1,784.70-4,694.376.48-379.780.0259--76.65---1.52--18.00--
LungLife AI Inc36.95k-4.35m18.55m19.00--1.23--502.06-0.1706-0.17060.00150.24940.0038--0.14741,944.93-44.11---50.09--100.00---11,767.39------0.0419--91.67--28.83------
Data as of Apr 24 2024. Currency figures normalised to Synairgen PLC's reporting currency: UK Pound GBX

Institutional shareholders

28.79%Per cent of shares held by top holders
HolderShares% Held
TFG Asset Management UK LLPas of 26 Apr 202356.70m28.15%
Toscafund Asset Management LLPas of 31 Dec 20221.28m0.64%
Premier Fund Managers Ltd.as of 30 Apr 20230.000.00%
Data from 30 Sep 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.